a8

5. (Amended) A composition of claim 4, wherein the active agent is selected from the group consisting of bisacodyl, famotidine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.

Please amend claim 9 as follows:

a9

9. (Amended) A composition of claim 3 having from about 19 wt% to about 27 wt% silicified microcrystalline cellulose and having from about 31 wt% to about 39 wt% magnesium aluminometasilicate

Please amend claim 14 as follows:

a10

14. (Amended) A solid oral dosage form of claim 13, wherein the weight ratio of simethicone to silicified microcrystalline cellulose and magnesium aluminometasilicate is at least about 0.50.

Please amend claim 17 as follows:

a11

17. (Amended) A solid oral dosage form of claim 16, wherein the active agent is selected from the group consisting of bisacodyl, famotidine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.

Please amend claim 23 as follows:

23. (Amended) A solid oral dosage form of claim 13, wherein the compressed admixture is a tablet having a hardness value of at least 2 kp/cm^2.

a12

Please amend claim 24 as follows:

24. (Amended) A solid oral dosage form of claim 13, wherein the compressed admixture is a tablet having a hardness value of from about 5 to about 10 kp/cm^2.

Please amend claim 26 as follows:

a13

26. (Amended) A compressed solid dosage form comprising an admixture of simethicone, silicified microcrystalline cellulose, magnesium aluminometasilicate, wherein the weight ratio of simethicone to silicified microcrystalline cellulose and magnesium aluminometasilicate is at least about 0.50.